



## Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering

August 4, 2015

DEVON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc., announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of \$14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388, or by email at [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com), or by accessing the SEC's website at [www.sec.gov](http://www.sec.gov).

A registration statement on Form S-1 relating to these securities was declared effective by the Securities and Exchange Commission on August 4, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is evaluating two product candidates, ZYN002 and ZYN001, in five indications. ZYN002, the company's CBD Gel, is the first and only synthetic CBD formulated as a patent protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. Zynerba is also developing ZYN001, which utilizes a synthetically manufactured pro-drug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. ZYN001 will be studied in fibromyalgia and peripheral neuropathic pain. Learn more at [www.zynerba.com](http://www.zynerba.com) and follow the company on Twitter at [@ZynerbaPharma](https://twitter.com/ZynerbaPharma).

### Investor Contact:

Armando Anido  
Chairman and CEO  
Zynerba Pharmaceuticals  
484.581.7505

### Media Contact:

Jennifer Guinan  
Sage Strategic Marketing  
610.410.8111  
[Jennifer@sagestrat.com](mailto:Jennifer@sagestrat.com)

[Zynerba Pharmaceuticals Logo](#)

Zynerba Pharmaceuticals